Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Open-Label Trial to Evaluate Enoblituzumab in Combination With Retifanlimab or Tebotelimab in the First-Line Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

NCT04634825 is registered in ClinicalTrials.gov with MacroGenics as lead sponsor.

NCT NCT04634825
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04634825 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Open-Label Trial to Evaluate Enoblituzumab in Combination With Retifanlimab or Tebotelimab in the First-Line Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Lead sponsor
MacroGenics
Phase
Phase 2
Overall status
Terminated
Start date
March 17, 2021
Completion date
July 29, 2022
Enrollment
62 (actual)
Sites
42

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck cancer, head and neck neoplasms, head and neck squamous cell carcinoma